Most patients who developed eosinophilic esophagitis during oral immunotherapy experienced resolution in their EoE symptoms without stopping OIT, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
When EoE develops, providers should consider halting OIT after pharmacologic treatment fails, Na’ama Epstein-Rigbi, MD, Institute of Allergy, Immunology and Pediatric Pulmonology, Shamir Medical Center, and colleagues wrote.
“While non-immediate gastrointestinal adverse reactions are quite common during OIT, the actual findings of EoE are rarer